Taysha Gene Therapies, Inc. Interest Expense Nonoperating
Taysha Gene Therapies, Inc. (TSHA) reported Interest Expense Nonoperating of $6.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-11
- Taysha Gene Therapies, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $6.00K, a 64.71% decline year-over-year.
- Taysha Gene Therapies, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $9.00K, a 52.63% decline year-over-year.
- Taysha Gene Therapies, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $12.00K, a 45.45% decline year-over-year.
- Taysha Gene Therapies, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $15.00K, a 37.50% decline year-over-year.
- Taysha Gene Therapies, Inc. interest expense nonoperating for fiscal 2025 was $63.00K, a 38.24% decline from fiscal 2024.
- Taysha Gene Therapies, Inc. interest expense nonoperating for fiscal 2024 was $102.00K, a 97.96% decline from fiscal 2023.
- Taysha Gene Therapies, Inc. interest expense nonoperating for fiscal 2023 was $5.00M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.00K 10-Q · filed 2026-08-11 | $15.00K 10-Q · filed 2026-08-11 | $27.00K derived: sum of 3 quarters · filed 2026-08-11 | $42.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $9.00K 10-Q · filed 2026-05-06 | $21.00K derived: sum of 2 quarters · filed 2026-05-06 | $36.00K derived: sum of 3 quarters · filed 2026-05-06 | $53.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $27.00K derived: sum of 2 quarters · filed 2026-03-19 | $44.00K derived: sum of 3 quarters · filed 2026-08-11 | $63.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $15.00K 10-Q · filed 2025-11-04 | $32.00K derived: sum of 2 quarters · filed 2026-08-11 | $51.00K 10-Q · filed 2025-11-04 | $73.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $17.00K 10-Q · filed 2026-08-11 | $36.00K 10-Q · filed 2026-08-11 | $58.00K derived: sum of 3 quarters · filed 2026-08-11 | $82.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $19.00K 10-Q · filed 2026-05-06 | $41.00K derived: sum of 2 quarters · filed 2026-05-06 | $65.00K derived: sum of 3 quarters · filed 2026-05-06 | $92.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $46.00K derived: sum of 2 quarters · filed 2026-03-19 | $73.00K derived: sum of 3 quarters · filed 2026-03-19 | $102.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $24.00K 10-Q · filed 2025-11-04 | $51.00K derived: sum of 2 quarters · filed 2025-11-04 | $80.00K 10-Q · filed 2025-11-04 | $793.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $27.00K 10-Q · filed 2025-08-12 | $56.00K 10-Q · filed 2025-08-12 | $769.00K derived: sum of 3 quarters · filed 2025-08-12 | $2.24M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $29.00K 10-Q · filed 2025-05-15 | $742.00K derived: sum of 2 quarters · filed 2025-05-15 | $2.21M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $713.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.18M derived: sum of 2 quarters · filed 2025-02-26 | $5.00M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $1.47M 10-Q · filed 2024-11-13 | $4.29M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |